KR20210095734A - 신경정신계 장애의 치료를 위한 조성물 및 방법 - Google Patents

신경정신계 장애의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20210095734A
KR20210095734A KR1020217023520A KR20217023520A KR20210095734A KR 20210095734 A KR20210095734 A KR 20210095734A KR 1020217023520 A KR1020217023520 A KR 1020217023520A KR 20217023520 A KR20217023520 A KR 20217023520A KR 20210095734 A KR20210095734 A KR 20210095734A
Authority
KR
South Korea
Prior art keywords
disorder
component
acid
treatment
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217023520A
Other languages
English (en)
Korean (ko)
Inventor
이동현
Original Assignee
주식회사 제네리스코리아
듀크 유니버서티
제네리스 바이오파머슈티컬스 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 제네리스코리아, 듀크 유니버서티, 제네리스 바이오파머슈티컬스 코퍼레이션 filed Critical 주식회사 제네리스코리아
Priority to KR1020227017187A priority Critical patent/KR20220071297A/ko
Publication of KR20210095734A publication Critical patent/KR20210095734A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
KR1020217023520A 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법 Ceased KR20210095734A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227017187A KR20220071297A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562108616P 2015-01-28 2015-01-28
US62/108,616 2015-01-28
KR1020207007722A KR20200032759A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
PCT/KR2016/000903 WO2016122218A2 (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007722A Division KR20200032759A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017187A Division KR20220071297A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20210095734A true KR20210095734A (ko) 2021-08-02

Family

ID=56544502

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020217023520A Ceased KR20210095734A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020187003387A Active KR101994596B1 (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020207007722A Ceased KR20200032759A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020197017975A Ceased KR20190077590A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020167021256A Ceased KR20160103548A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020227017187A Ceased KR20220071297A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020187003387A Active KR101994596B1 (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020207007722A Ceased KR20200032759A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020197017975A Ceased KR20190077590A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020167021256A Ceased KR20160103548A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법
KR1020227017187A Ceased KR20220071297A (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Country Status (8)

Country Link
US (4) US20170326127A1 (https=)
EP (2) EP3251699B1 (https=)
JP (4) JP6655090B2 (https=)
KR (6) KR20210095734A (https=)
CN (2) CN107206093A (https=)
DK (1) DK3251699T3 (https=)
ES (1) ES2985064T3 (https=)
WO (1) WO2016122218A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4729123A2 (en) * 2017-04-24 2026-04-22 Alto Neuroscience, Inc. Compositions comprising pramipexole and a 5ht3 antagonist for use in treating depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR102176538B1 (ko) 2019-01-31 2020-11-09 한국과학기술연구원 항정신병성 약물 검출용 fret 바이오센서 및 이를 이용한 검출 방법
CA3210839A1 (en) * 2021-03-06 2022-09-15 Matthias Emanuel LIECHTI Using geno- or phenotyping to adjust lsd dosing
CN117355302A (zh) 2021-04-30 2024-01-05 思维医学股份有限公司 Lsd盐晶体形式
JP2024529727A (ja) 2021-08-19 2024-08-08 マインド メディシン， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
WO1997003671A1 (en) * 1995-07-14 1997-02-06 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
DK2009000T3 (da) 2003-01-16 2011-09-05 Acadia Pharm Inc Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
KR20070087678A (ko) * 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
US7686560B2 (en) * 2005-12-08 2010-03-30 Conestoga Cold Storage Rack, conveyor and shuttle automated pick system
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CN105168219B (zh) * 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
US20130116215A1 (en) * 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders

Also Published As

Publication number Publication date
JP2023109947A (ja) 2023-08-08
US20170326127A1 (en) 2017-11-16
JP6943994B2 (ja) 2021-10-06
KR20220071297A (ko) 2022-05-31
EP3251699A4 (en) 2018-08-01
ES2985064T8 (en) 2025-03-07
US12311056B2 (en) 2025-05-27
JP6655090B2 (ja) 2020-02-26
JP2021193118A (ja) 2021-12-23
DK3251699T3 (da) 2024-05-21
EP3251699A2 (en) 2017-12-06
EP4385575A3 (en) 2024-08-28
WO2016122218A3 (ko) 2016-10-13
WO2016122218A2 (ko) 2016-08-04
KR20180015302A (ko) 2018-02-12
US20230293443A1 (en) 2023-09-21
US20200197383A1 (en) 2020-06-25
CN114146088A (zh) 2022-03-08
JP2018503677A (ja) 2018-02-08
CN107206093A (zh) 2017-09-26
JP2020075938A (ja) 2020-05-21
KR20190077590A (ko) 2019-07-03
JP7594045B2 (ja) 2024-12-03
ES2985064T3 (es) 2024-11-04
US20250255823A1 (en) 2025-08-14
EP4385575A2 (en) 2024-06-19
KR101994596B1 (ko) 2019-06-28
EP3251699B1 (en) 2024-04-17
KR20160103548A (ko) 2016-09-01
KR20200032759A (ko) 2020-03-26
JP7288016B2 (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
JP7594045B2 (ja) 薬学的組成物
JP2022168136A (ja) ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物
US8354447B2 (en) mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression
JP2016020385A (ja) 治療処置の副作用の低減のための方法および組成物
JP2005531631A (ja) 禁煙促進方法
WO2019104291A1 (en) Combination of granulated dried botanical extract powder for symptom relief
JP6181754B2 (ja) トゥレット症候群治療のための縮合ベンゾアゼピン
CN101014325A (zh) 治疗中枢神经系统病症的药物
WO2019100057A1 (en) Use of morphinans for treating cocaine addiction, pruritis, and seizure disorders
EP3545955A1 (en) Drug for treating cocaine addiction or preventing recurrence of same
Dassanayake et al. Replacement treatment during extinction training with the atypical dopamine uptake inhibitor, JHW-007, reduces relapse to methamphetamine seeking
JP2007246507A (ja) 疲労の予防・治療組成物及び予防・治療方法
HK40065451A (en) Ecopipam for treatment of tourettes syndrome

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210723

Application number text: 1020207007722

Filing date: 20200316

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210823

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220320

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210823

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20220520

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220320

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101001185

Request date: 20220520

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101001185; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20220520

Effective date: 20230817

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230817

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20220520

Decision date: 20230817

Appeal identifier: 2022101001185